E2A-PBX1

• About this biomarker
• Introduction to our products
• Why choose our products
• Main product for E2A-PBX1
• Associated products
• Related publications

The leukemogenic fusion gene transcript E2A-PBX1 results from fusion of the E2A and PBX1 (formerly prl) genes, through the t(1;19)(q23;p13).The E2A-PBX1 fusion gene is found in 3-5% of childhood and in 3% of adult precursor-B-ALL.

In 95% of the cases, E2A-PBX1 transcripts are expressed. This expression is tightly associated with detection of cytoplasmic Ig M chains.

E2A-PBX1 FusionQuant® technology uses Real-Time Quantitative RQ-PCR to quantify the expression level of specific E2A-PBX1 fusion gene transcripts relative to ABL control gene.

Quantification of E2A-PBX1  fusion gene transcripts has been standardized in the EAC (Europe Against Cancer) program  [Gabert J et al. Leukemia. 2003, Beillard E et al. Leukemia. 2003], and IPSOGEN FusionQuant® kits use this validated technology to calibrate and normalize RQ-PCR results.

Why choose E2A-PBX1  FusionQuant® Standards?

• EAC Standardized RQ-PCR procedures

• Compatibility with most RQ-PCR platforms

• Calibrated and sensitive quantification of fusion gene transcript, normalized with ABL (BCR or GUS) control gene (results in NCN)

• Ready-to-Use plasmid standards

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia. 2003
Authors: Gabert J et al.

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 2003
Authors: Beillard E et al.